Robert Kloppenburg
Directeur/Bestuurslid bij Institute for Healthcare Communication, Inc.
Profiel
Robert Kloppenburg is currently the Director at the Institute for Healthcare Communication, Inc. He previously worked as the Senior Director of Corporate Communications at Millennium Pharmaceuticals, Inc. from 2001 to 2003.
He also held positions as the VP of Investor Relations & Corporate Communications at Synta Pharmaceuticals Corp., the SVP & Head of Boston Life Sciences Practice at Fleishman-Hillard, Inc., and the VP of Corporate Communications & Public Affairs at AVEO Pharmaceuticals, Inc. Kloppenburg received his undergraduate degree from Carleton University.
Actieve functies van Robert Kloppenburg
| Bedrijven | Functie | Begin |
|---|---|---|
| Institute for Healthcare Communication, Inc. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Robert Kloppenburg
| Bedrijven | Functie | Einde |
|---|---|---|
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Public Communications Contact | 01-01-2003 |
| AVEO PHARMACEUTICALS, INC. | Investor Relations Contact | - |
Fleishman-Hillard, Inc.
 Fleishman-Hillard, Inc. Miscellaneous Commercial ServicesCommercial Services Fleishman Hillard, Inc. is a strategic communications company. It provides public relations, public affairs and marketing communications services. The company was founded in 1946 and is headquartered in St. Louis, MO. | Corporate Officer/Principal | - |
Synta Pharmaceuticals Corp.
 Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | Investor Relations Contact | - |
Opleiding van Robert Kloppenburg
| Carleton University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | Health Technology |
Fleishman-Hillard, Inc.
Fleishman-Hillard, Inc. Miscellaneous Commercial ServicesCommercial Services Fleishman Hillard, Inc. is a strategic communications company. It provides public relations, public affairs and marketing communications services. The company was founded in 1946 and is headquartered in St. Louis, MO. | Commercial Services |
AVEO Pharmaceuticals, Inc.
 AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA. | Health Technology |
| Institute for Healthcare Communication, Inc. |
